AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30374683
Drug: Single ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses (1500, 3000, 4500 or 6000 mg CBD)
Trial: 30374683
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose (750 or 1500 mg CBD)
Trial: 27382815
Drug: Group M:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group M: 15 ml of bupivacaine 0.5% + 1 ml of 50 mg MgSO4
Trial: 27382815
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 15 ml of bupivacaine 0.5% + 1 ml of normal saline
Trial: 25699352
Drug: Warm water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm water infusion
Trial: 10402814
Drug: Propofol titration
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol titration using BIS maintained at 40 during induction (n = 15)
Trial: 10402814
Drug: Bolus infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus infusion of propofol 2 mg.kg‐1 (n = 15)
Trial: 10402814
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (titration and bolus)
Trial: 7538179
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment using imipenem/cilastatin sodium (IPM/CS) with G-CSF
Trial: 7538179
Drug: Monotherapy on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy on antibiotic
Trial: 7538179
Drug: IPM/CS in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPM/CS in combination with other antibiotics
Trial: 7303774
Drug: Short-term lithium
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term lithium therapy (7 days) in combination with methimazole
Trial: 7303774
Drug: Methimazole monotherapy
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole monotherapy
Trial: 31615388
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of β‐AB and Ivabradine
Trial: 28728604
Drug: CPT (clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT (clinical prediction tool) with matched treatment recommendation
Trial: 11213884
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg once daily
Trial: 11213884
Drug: Rosiglitazone 8
RxNorm normalized name: rosiglitazone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 8 mg once daily
Trial: 7914307
Drug: 500 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 U/kg rhEPO subcutaneously twice a week for 3 weeks
Trial: 2885878
Drug: Carbamazepine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (average dose 1240 mg/day, blood levels 10.4 +/- 2.2 micrograms/ml)
Trial: 30015503
Drug: Cognitive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive treatment control (n=24, 8 women and 16 men)
Trial: 7560400
Drug: Full-mouth disinfection
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth disinfection with removal of all plaque and calculus in two visits within 24 hours, tongue brushed with 1% chlorhexidine gel, mouth rinsed with 0.2% chlorhexidine solution, subgingival chlorhexidine (1%) irrigation performed in all pockets
Trial: 24138688
Drug: Combination beclometasone/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination beclometasone/formoterol hydrofluoroalkane (HFA)‐MDI used as both maintenance and reliever therapy
Trial: 24138688
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of maintenance beclometasone/formoterol HFA‐MDI with salbutamol MDI for relief
Trial: 21719783
Drug: Allopurinol 300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg/d
Trial: 15234403
Drug: Reperfusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reperfusion therapy for acute STEMI
Trial: 11236835
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment for both alcohol and social anxiety problems (n = 49)
Trial: 11236835
Drug: Individual cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive behavioral therapy for alcoholism only (n = 44)
Trial: 8317644
Drug: Pethidine 100
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 100 mg added to 40 ml prilocaine 0.25%
Trial: 7841567
Drug: Empiric dosing
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric dosing
Trial: 18166191
Drug: High-dose B-vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose B-vitamin therapy
Trial: 16864642
Drug: Asthma-related events
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asthma-related events (oral steroid use, emergency department visits, hospitalizations)
Trial: 14650098
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GG administered orally in yogurt base (10^9 CFU) for 1 month, 1 or 2 doses per day
Trial: 1638713
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg captopril
Trial: 6395280
Drug: Cefonicid 1
RxNorm normalized name: cefonicid 1 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid 1 g intravenously or intramuscularly 1 hr before surgery
Trial: 6395280
Drug: Cefoxitin 2
RxNorm normalized name: cefoxitin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin 2 g intravenously or intramuscularly 1 hr before surgery and 2 g every 6 hr for 24 hr
Trial: 30200582
Drug: Whey Protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey Protein (WP, 77 g/day protein, 580 kcal/day)
Trial: 30200582
Drug: Carbohydrate (CHO,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO, 127 g/day carbohydrate, 580 kcal/day)
Trial: 25466429
Drug: Fexofenadine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine (60 mg)
Trial: 19639726
Drug: Olopatadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine (5 mg)
Trial: 20659611
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of phenylephrine at 0.15 microg.kg(‐1).min(‐1) after spinal block
Trial: 20659611
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of prophylactic phenylephrine 50 microg after spinal block
Trial: 20659611
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of phenylephrine 50 microg in case of hypotension
Trial: 17882915
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg pseudoephedrine (PSE) four times daily
Trial: 7549843
Drug: Cryopreserved marrow
RxNorm normalized name: Sus scrofa bone marrow preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryopreserved marrow cells using a mixture of 5% DMSO, 6% HES, and 4% Albumin in Lactated Ringer solution.
Trial: 80525
Drug: Tienilic acid
RxNorm normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tienilic acid (mean dose 210 mg)
Trial: 80525
Drug: Cyclopenthiazide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclopenthiazide (mean dose 0.41 mg)
Trial: 29446160
Drug: SPF30 daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SPF30 daily skin cream
Trial: 24736770
Drug: Medium Load
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium Load (ML: 12.5% BM)
Trial: 17600973
Drug: Monthly visit
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly visit schedule preference
Trial: 8117177
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate (200 mg daily)
Trial: 2455414
Drug: Etretinate +
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etretinate + PUVA treatment
Trial: 2455414
Drug: Etretinate monotherapy
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etretinate monotherapy
Trial: 2455414
Drug: Etretinate treatment
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etretinate treatment (control side)
Trial: 2071980
Drug: Multidrug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidrug therapy (MDT) for paucibacillary leprosy
Trial: 2071980
Drug: Dapsone (DDS)
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone (DDS) monotherapy
Trial: 40572
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg temazepam with alcohol
Trial: 40572
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg temazepam with alcohol
Trial: 40572
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg temazepam with alcohol
Trial: 23704198
Drug: Copenhagen Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copenhagen Physical Activity after Cancer Treatment (PACT)
Trial: 21339010
Drug: Intra-operative radiation
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-operative radiation therapy (IORT) combined with surgical resection (n=73)
Trial: 19013603
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg for 1 week run-in and 100 mg for 3 weeks)
Trial: 17804354
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (INT) including antidepressants and/or psychotherapy treatment plus EUC
Trial: 12022217
Drug: Intrathecal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal midazolam (2 mg) with 1.5 ml of 5% lignocaine
Trial: 12022217
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml of 5% lignocaine only
Trial: 2492235
Drug: Follicle-stimulating hormone
RxNorm normalized name: Follicle-stimulating hormone receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follicle-stimulating hormone (FSH) administered at different times during the menstrual cycle
Trial: 2492235
Drug: Clomiphene citrate,
RxNorm normalized name: ClomiPHENE Citrate, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate, 100 mg/day for days 2 to 6; FSH, 150 units/day for days 1 to 4; human menopausal gonadotropin, 150 units/day from day 5 until hCG administration
Trial: 4618908
Drug: Controlled trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled trials of treatment for liver disease in children
Trial: 31654838
Drug: Alectinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib 600 mg
Trial: 2969740
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg doxazosin
Trial: 27717996
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (hydration and analgesics only)
Trial: 31886707
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone implant
Trial: 16113424
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with budesonide and formoterol
Trial: 16113424
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with inhaled corticosteroids and long-acting beta-agonists
Trial: 16113424
Drug: Inhaled bronchodilators
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bronchodilators (tiotropium)
Trial: 11780699
Drug: Novel chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel chemotherapy and new biologic agents
Trial: 9623560
Drug: Pulse calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulse calcitriol (3.0 microg twice a week)
Trial: 9623560
Drug: Daily calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily calcitriol (0.75 microg a day)
Trial: 9623560
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (pulse and daily calcitriol)
Trial: 7843579
Drug: Triazolam (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.125 mg, with option to increase to 0.25 mg)
Trial: 18703440
Drug: Combined pharmacologic
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pharmacologic and behavioral smoking cessation intervention (10-week group intervention + nicotine replacement therapy)
Trial: 15989013
Drug: noliprel (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: noliprel (2 mg/0.625 mg)
Trial: 15989013
Drug: caposide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: caposide (50 mg/25 mg)
Trial: 7000589
Drug: Chromium-rich brewers'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium-rich brewers' yeast (9 g daily for 8 weeks)
Trial: 31252146
Drug: Ketoconazole gel-flakes
RxNorm normalized name: ketoconazole Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole gel-flakes (50 mg/daily for three days)
Trial: 31252146
Drug: Gynoconazol vaginal
RxNorm normalized name: lanoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gynoconazol vaginal cream (80 mg terconazole/daily for three days)
Trial: 25591635
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy including reflex action and tizanidine
Trial: 25591635
Drug: Standard methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard methods (reflex therapy of СЕЕР and local injections of a combination of local anesthetics with small doses of steroids)
Trial: 22456862
Drug: Energy drink
RxNorm normalized name: Boost Energy Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy drink containing 80 mg of caffeine plus alcohol (0.046 and 0.087% breathalyser alcohol concentration)
Trial: 20380913
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cannabis (19 mg delta‐9‐THC)
Trial: 20380913
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cannabis
Trial: 20380913
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high dose cannabis and alcohol
Trial: 12711931
Drug: Alcohol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.5 g/kg, 10% w/v)
Trial: 12711931
Drug: 4‐methylpyrazole (10‐15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐methylpyrazole (10‐15 mg/kg orally)
Trial: 8590608
Drug: Ethanol 0.55
RxNorm normalized name: ethanol 0.55 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.55 g/kg
Trial: 8739611
Drug: Ethanol 0.85
RxNorm normalized name: ethanol 0.85 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.85 g/kg
Trial: 9377589
Drug: Phosphatidylcholine (PCh)
RxNorm normalized name: phosphatidylcholine, soybean
DrugBank: Lecithin (DB15834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylcholine (PCh) 25 g
Trial: 9377589
Drug: Phosphatidylcholine (PCh)
RxNorm normalized name: phosphatidylcholine, soybean
DrugBank: Lecithin (DB15834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylcholine (PCh) 10 g
Trial: 31124194
Drug: GSK2981710 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2981710 (30 g/day)
Trial: 27383499
Drug: Dexmedetomidine (4μg/mL)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (4μg/mL) with 2mL load, 1.5ml background infusion, 0.5mL single dose, 20s locking time
Trial: 27383499
Drug: Dexmedetomidine (4μg/mL)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (4μg/mL)
Trial: 16877896
Drug: Risperidone (4-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (4-6 mg/day)
Trial: 17578722
Drug: E2 (Estrofem,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 (Estrofem, Novo Nordisk, Copenhagen, Denmark) 2 mg/d given orally over 3 months
Trial: 15176764
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Therapy (CRT) (n = 18)
Trial: 15176764
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (occupational therapy activities) (n = 14)
Trial: 15176764
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (n = 19)
Trial: 22743160
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment types
Trial: 12490825
Drug: Venlafaxine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine therapy
Trial: 12490825
Drug: Other antidepressants
RxNorm normalized name: Other antidepressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antidepressants (including tricyclic antidepressants and selective serotonin reuptake inhibitors)
Trial: 11475716
Drug: Integrated traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated traditional Chinese and Western Medicine (TCM‐WM)
Trial: 11475716
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine alone (Control)
Trial: 1842458
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low‐molecular dextran or low‐molecular hydroxyethyl starch and hyperbaric oxygenation
Trial: 6889714
Drug: Cyclophosphamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide plus cisplatin (combination chemotherapy)
Trial: 6889714
Drug: Cyclophosphamide (single-agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (single-agent chemotherapy)
Trial: 28139349
Drug: Ozanezumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanezumab (15 mg/kg)
Trial: 24918330
Drug: Subparaneural injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subparaneural injection of 0.3 mL/kg mepivacaine 10 mg/mL
Trial: 24918330
Drug: Circumferential extraneural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circumferential extraneural injection of 0.3 mL/kg mepivacaine 10 mg/mL
Trial: 24918330
Drug: Unintentional intraepineural
RxNorm normalized name: HYALURONIC ACID 2.5 g INTRAEPIDERMAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unintentional intraepineural injection
Trial: 15334437
Drug: Biofeedback-assisted cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback-assisted cognitive-behavioral treatment (BF/CBT)
Trial: 11322865
Drug: Conventional drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drugs in different combinations
Trial: 11322865
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment approaches for refractory cGvHD
Trial: 9853887
Drug: Methotrexate treatment
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate treatment (1 mg/kg injected transvaginally or intramuscularly)
Trial: 8011799
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) 0.25, 0.5, and 1.0 mg
Trial: 7143011
Drug: Cyproheptadine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine (6 mg to 24 mg per day)